Author

R. B. Lock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Avila· 1 shared A. H. Wei· 1 shared A. J. Gifford· 1 shared A. K. Enjeti· 1 shared A. M. Douglas· 1 shared A. M. Fordham· 1 shared A. Mannan· 1 shared A. Salib· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Avila

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas

A. M. Fordham, L. M. Brown, C. Mayoh, A. Salib, Z. A. Barger, M. Wong, T. C. C. L. K. Sian, J. Xie, K. Gunther, P. Trebilcock, R. L. Terry, P. Barahona, P. Ajuyah, A. Sherstyuk, A. Avila, , E. D. Fleuren

The paper identifies FGFR aberrations as actionable targets in pediatric and AYA sarcomas using multi-platform profiling and shows FGFR inhibitors can inhibit tumor growth in PDX models.

bioRxiv · Jul 19, 2023 · PreprintCancer Biology

Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies

Z. P. Germon, J. R. Sillar, A. Mannan, R. J. Duchatel, D. Staudt, H. C. Murray, I. J. Findlay, E. R. Jackson, H. P. McEwen, A. M. Douglas, T. Mclachlan, J. E. Schjenken, D. A. Skerrett-Byrne, H. Huang, M. N. Melo-Braga, , M. D. Dun

This study identifies the Rac-NOX2 complex as a driver of redox signaling in FLT3-mutant AML, showing that inhibiting NOX2 reduces key signaling pathways and enhances response to FLT3 inhibitors.

bioRxiv · Mar 9, 2022 · PreprintCancer Biology